ABSTRACT
Negative and positive symptoms were determined for 46 drug-free patients who met Research Diagnostic Criteria (RDC) and/or Feighner criteria for schizophrenia. A modified version of the Scale for the Assessment of Negative Symptoms (SANS) was completed for each patient based on items from the Schedule for Affective Disorders and Schizophrenia (SADS) and other scales. Positive symptoms were scored from the SADS as well as from the following four diagnostic systems: RDC, Schneider's first-rank symptoms, the 12-point Flexible system, and Langfeldt's criteria for poor prognosis schizophrenia. For all patients, there was no correlation of negative symptoms and positive symptoms defined by any diagnostic system. Within the paranoid and undifferentiated subtypes, there was a positive correlation of positive and negative symptoms. Patients moving from stable to exacerbated states had an increase in both positive and negative symptoms, and patients with a poor history of treatment response had both more positive and more negative symptoms than responsive patients in a stable state. These results do not support the view that subgroups of patients have predominantly either negative or positive symptoms.
Subject(s)
Schizophrenia/diagnosis , Schizophrenic Psychology , Adult , Attention , Cognition Disorders/diagnosis , Delusions/diagnosis , Drive , Hallucinations/diagnosis , Humans , Male , Middle Aged , Motivation , Psychiatric Status Rating Scales , Psychometrics , ThinkingABSTRACT
A new rating instrument, the Alzheimer's Disease Assessment Scale, was designed specifically to evaluate the severity of cognitive and noncognitive behavioral dysfunctions characteristic of persons with Alzheimer's disease. Item descriptions, administration procedures, and scoring are outlined. Twenty-seven subjects with Alzheimer's disease and 28 normal elderly subjects were rated on 40 items. Twenty-one items with significant intraclass correlation coefficients for interrater reliability (range, .650-.989) and significant Spearman rank-order correlation coefficients for test-retest reliability (range, .514-1) constitute the final scale. Subjects with Alzheimer's disease had significantly more cognitive and noncognitive dysfunction than the normal elderly subjects.
Subject(s)
Alzheimer Disease/diagnosis , Psychiatric Status Rating Scales , Aged , Alzheimer Disease/psychology , Cognition Disorders/diagnosis , Cognition Disorders/psychology , Female , Humans , Male , Middle Aged , PsychometricsABSTRACT
A study was conducted to determine the interrater reliability and the inter-informant reliability of two rating scales commonly used with schizophrenic patients. Both scales were completed by two informants for each of 45 schizophrenics. The Levels of Functioning Scale, which measures current social functioning, gave consistent results both between raters and between informants. The Premorbid Asocial Adjustment Scale, which measures social functioning during childhood and adolescence, produced very high reliability between raters but very poor reliability between informants. This suggests that much of the data collected about premorbid adjustment of schizophrenic patients are not accurate and that attempts to correlate reported premorbid adjustment with biological measures may be invalid. Ways of increasing the reliability and validity of premorbid adjustment measures are discussed.
Subject(s)
Psychiatric Status Rating Scales , Schizophrenic Psychology , Social Adjustment , Adult , Family , Humans , Male , Middle Aged , Psychometrics , Retrospective StudiesSubject(s)
Alzheimer Disease/diagnosis , Dementia/diagnosis , Aged , Alzheimer Disease/psychology , Female , Humans , Intelligence , Language , Male , Memory , Middle Aged , Psychological Tests , Psychomotor PerformanceSubject(s)
Alzheimer Disease/psychology , Psychiatric Status Rating Scales , Aged , Alzheimer Disease/therapy , Female , Humans , Male , Middle AgedSubject(s)
Alzheimer Disease/diagnosis , Dementia/diagnosis , Aged , Alzheimer Disease/psychology , Humans , Middle AgedABSTRACT
Elderly subjects were recruited for a study of the effect of intravenous physostigmine on the memory disturbance of Alzheimer's Disease. Approximately one out of every twelve people screened was suitable for the study. Subjects were ruled out either because they did not meet research diagnostic criteria for AD, because they could not cooperate with the studies or because of medical contraindications. The data indicate that large numbers of potential subjects are required to select relatively small groups for pharmacological studies. The implications of some of these developments for future research are discussed.
Subject(s)
Aging , Clinical Trials as Topic/methods , Aged , Alzheimer Disease/complications , Female , Humans , Male , Memory Disorders/drug therapy , Memory Disorders/etiology , Middle Aged , Physostigmine/therapeutic useABSTRACT
Fourteen case histories of persons who had a histological diagnosis of either senile dementia of the Alzheimer type, multiinfarct dementia, or a mixed dementia composed of these two types and who showed evidence of a moderate to severe dementia on psychological testing were rated for the presence of thirteen clinical features comprising Hachinski's Ischemic Score. These features are frequently considered primarily characteristic of vascular dementia. Persons with senile dementia of the Alzheimer type were clearly differentiable from persons with multiinfarct dementia and mixed dementia, while the latter two groups were indistinguishable from one another. In our sample, eight features were found to characterize those persons with vascular dementia. These data verify the usefulness of the Ischemic Score in differentiating between senile dementia of the Alzheimer type and vascular dementia.
